SK 1080

Drug Profile

SK 1080

Alternative Names: KR 31080

Latest Information Update: 25 Mar 2008

Price : $50

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Korea Research Institute of Chemical Technology; SK Pharma
  • Class Antihypertensives; Imidazoles; Pyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Hypertension in South Korea (PO)
  • 12 Jun 1998 Preclinical development for Hypertension in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top